S4 Ep20: Not So Different: How Biosimilar Companies Are Stepping Up Their Game to Compete Against Originators
Despite some biosimilars, including those for filgrastim, trastuzumab, and bevacizumab, achieving a greater US market share than their originators, other biosimilar categories, such as pegfilgrastim and infliximab, are still trailing behind. Some biosimilar companies are becoming more savvy, developing new ways to make a bigger statement in the market.
We sat down with Kirollos Hanna, PharmD...
4m
•
Sep 19, 2021